基因型、氧化酶状态及移植前感染或自身炎症不影响慢性肉芽肿病的异基因造血干细胞移植结局
该多机构回顾性及前瞻性研究纳入391例慢性肉芽肿病(CGD)患者,比较常规治疗(非移植,2004-2018年入组)与造血干细胞移植(HCT,1996-2018年)的结局。HCT后中位随访3.7年,3年总生存率82%、无事件生存率69%;多变量分析显示Lansky/Karnofsky评分<90及使用HLA不合供者负向影响生存,而年龄、基因型及氧化酶状态不影响结局。移植前活动性感染或炎症不影响HCT生存,但移植前炎症状态与慢性移植物抗宿主病相关;17.6%患者发生植入失败或接受第二次HCT,与美法仑为基础预处理和/或早期混合嵌合相关。HCT可持久缓解CGD症状并降低疾病负担,活动性感染或炎症患者是移植候选者,应在发生可能影响体能状态的合并症前考虑HCT。
要点
- HCT后3年总生存率82%、无事件生存率69%,中位随访3.7年。
- Lansky/Karnofsky评分<90及HLA不合供者负向影响生存;年龄、基因型、氧化酶状态不影响结局。
- 移植前活动性感染或炎症不 adverse 影响HCT生存,但炎症状态与慢性GVHD相关。
核心结论
- HCT可持久缓解CGD症状并降低疾病负担;活动性感染或炎症患者是移植候选者,应在发生可能影响体能状态的合并症前考虑HCT。
研究设计与样本
- 多机构回顾性及前瞻性研究,纳入391例CGD患者,常规治疗(非HCT)组于2004-2018年入组,HCT组于1996-2018年接受移植。
主要发现
- HCT后中位随访3.7年,3年总生存率82%,无事件生存率69%。
- 多变量分析中,Lansky/Karnofsky评分<90和使用HLA不合供者负向影响生存;年龄、基因型和氧化酶状态不影响结局。
- 移植前患者感染密度更高、非感染性肺和肝病频率更高、类固醇使用更多,但这些未对HCT生存产生不良影响。
- 移植前存在炎症状态与慢性移植物抗宿主病相关。
- 17.6%的患者发生植入失败或接受第二次HCT,与美法仑为基础预处理和/或早期混合嵌合相关。
临床怎么用
- 活动性感染或炎症患者是移植候选者;作者认为应在发生可能影响体能状态的合并症前考虑HCT。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic granulomatous disease (CGD) is a primary immunodeficiency characterized by life-threatening infections and inflammatory conditions. Hematopoietic cell transplantation (HCT) is the definitive treatment for CGD, but questions remain regarding patient selection and impact of active disease on transplant outcomes. We performed a multi-institutional retrospective and prospective study of 391 patients with CGD treated either conventionally (non-HCT) enrolled from 2004 to 2018 or with HCT from 1996 to 2018. Median follow-up after HCT was 3.7 years with a 3-year overall survival of 82% and event-free survival of 69%. In a multivariate analysis, a Lansky/Karnofsky score <90 and use of HLA-mismatched donors negatively affected survival. Age, genotype, and oxidase status did not affect outcomes. Before HCT, patients had higher infection density, higher frequency of noninfectious lung and liver diseases, and more steroid use than conventionally treated patients; however, these issues did not adversely affect HCT survival. Presence of pre-HCT inflammatory conditions was associated with chronic graft-versus-host disease. Graft failure or receipt of a second HCT occurred in 17.6% of the patients and was associated with melphalan-based conditioning and/or early mixed chimerism. At 3 to 5 years after HCT, patients had improved growth and nutrition, resolved infections and inflammatory disease, and lower rates of antimicrobial prophylaxis or corticosteroid use compared with both their baseline and those of conventionally treated patients. HCT leads to durable resolution of CGD symptoms and lowers the burden of the disease. Patients with active infection or inflammation are candidates for transplants; HCT should be considered before the development of comorbidities that could affect performance status. This trial was registered at www.clinicaltrials.gov as #NCT02082353.
引用
- Leiding JW, Arnold DE, Parikh S, et al. Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD. Blood. 2023. PMID: 37562003. doi:10.1182/blood.2022019586
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。